Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Page 1
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism.
Watts NB, Bilezikian JP, Bone HG, Clarke BL, Denham D, Levine MA, Mannstadt M, Peacock M, Rothman JG, Vokes TJ, Warren ML, Yin S, Sherry N, Shoback DM. Watts NB, et al. Among authors: bilezikian jp. J Endocr Soc. 2023 Apr 4;7(5):bvad043. doi: 10.1210/jendso/bvad043. eCollection 2023 Mar 6. J Endocr Soc. 2023. PMID: 37091306 Free PMC article.
CONTEXT: Chronic hypoparathyroidism is conventionally treated with oral calcium and active vitamin D to reach and maintain targeted serum calcium and phosphorus levels, but some patients remain inadequately controlled. OBJECTIVE: To assess long-term safety and efficacy of …
CONTEXT: Chronic hypoparathyroidism is conventionally treated with oral calcium and active vitamin D to reach and maintain targeted serum ca …
Parathyroid Hormone Therapy for Managing Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis.
Yao L, Li J, Li M, Lin C, Hui X, Tamilselvan D, Kandi M, Sreekanta A, Makhdami N, Ali DS, Dandurand K, Yang K, Bilezikian JP, Brandi ML, Clarke BL, Mannstadt M, Rejnmark L, Khan AA, Guyatt G. Yao L, et al. Among authors: bilezikian jp. J Bone Miner Res. 2022 Dec;37(12):2654-2662. doi: 10.1002/jbmr.4676. Epub 2022 Nov 16. J Bone Miner Res. 2022. PMID: 36385517 Free article.
The efficacy and safety of parathyroid hormone (PTH) therapy for managing long-term hypoparathyroidism is being evaluated in ongoing clinical trials. ...
The efficacy and safety of parathyroid hormone (PTH) therapy for managing long-term hypoparathyroidism is being evaluated in ongoing …
Long-term consequences of osteoporosis therapy with denosumab.
Bandeira F, de Oliveira LB, Bilezikian JP. Bandeira F, et al. Among authors: bilezikian jp. Arch Endocrinol Metab. 2022 Nov 11;66(5):717-723. doi: 10.20945/2359-3997000000560. Arch Endocrinol Metab. 2022. PMID: 36382761 Free PMC article. Review.
Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey.
Van Uum S, Shrayyef M, M'Hiri I, Dandurand K, Ali DS, Bilezikian JP, Collins MT, Mannstadt M, Rubin MR, Siggelkow H, Tabacco G, Tay YD, Vokes T, Winer KK, Yao L, Guyatt G, Rejnmark L, Khan AA. Van Uum S, et al. Among authors: bilezikian jp. J Bone Miner Res. 2022 Dec;37(12):2630-2641. doi: 10.1002/jbmr.4698. Epub 2022 Nov 14. J Bone Miner Res. 2022. PMID: 36066096 Free article.
The goals of management for chronic HypoPT include improvement in QoL and the prevention of both hypo- and hypercalcemia symptoms and long-term complications. Several groups have provided consensus statements and guidelines on the management of HypoPT; however, due to limi …
The goals of management for chronic HypoPT include improvement in QoL and the prevention of both hypo- and hypercalcemia symptoms and long- …
Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop.
Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL, Rejnmark L, Shoback DM, Potts JT, Guyatt GH, Mannstadt M. Khan AA, et al. Among authors: bilezikian jp. J Bone Miner Res. 2022 Dec;37(12):2568-2585. doi: 10.1002/jbmr.4691. Epub 2022 Nov 14. J Bone Miner Res. 2022. PMID: 36054621 Free article.
To predict which patients will not develop permanent postsurgical HypoPT, we recommend evaluating serum PTH within 12 to 24 hours post total thyroidectomy (strong recommendation, moderate quality evidence). PTH > 10 pg/mL (1.05 pmol/L) virtually excludes long-term HypoP …
To predict which patients will not develop permanent postsurgical HypoPT, we recommend evaluating serum PTH within 12 to 24 hours post total …
Calcium Citrate Versus Calcium Carbonate in the Management of Chronic Hypoparathyroidism: A Randomized, Double-Blind, Crossover Clinical Trial.
Naciu AM, Tabacco G, Bilezikian JP, Santonati A, Bosco D, Incognito GG, Gaspa G, Manfrini S, Falchetti A, Trimboli P, Mazziotti G, Napoli N, Sanson G, Cesareo R, Vescini F, Palermo A. Naciu AM, et al. Among authors: bilezikian jp. J Bone Miner Res. 2022 Jul;37(7):1251-1259. doi: 10.1002/jbmr.4564. Epub 2022 Jun 24. J Bone Miner Res. 2022. PMID: 35466449 Free PMC article. Clinical Trial.
These results are likely to have clinical implications in HypoPT, particularly those who do not tolerate CaCO(3) and those affected by nephrolithiasis. A longer-term experience is needed to confirm these findings. 2022 The Authors. ...
These results are likely to have clinical implications in HypoPT, particularly those who do not tolerate CaCO(3) and those affected by nephr …
The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.
Chandran M, Bilezikian JP, Lau J, Rajeev R, Yang SP, Samuel M, Parameswaran R. Chandran M, et al. Among authors: bilezikian jp. Rev Endocr Metab Disord. 2022 Jun;23(3):485-501. doi: 10.1007/s11154-021-09694-6. Epub 2022 Jan 18. Rev Endocr Metab Disord. 2022. PMID: 35041148 Review.
In PHPT, cinacalcet lowers serum calcium and PTH with greater effects on calcium than on PTH in the short term. In the doses reported, the drug is safe with tolerable side effects. ...
In PHPT, cinacalcet lowers serum calcium and PTH with greater effects on calcium than on PTH in the short term. In the doses reported …
Post-acute COVID-19 syndrome.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Nalbandian A, et al. Among authors: bilezikian jp. Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22. Nat Med. 2021. PMID: 33753937 Free PMC article. Review.
Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of …
Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute …
Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism.
Gosmanova EO, Houillier P, Rejnmark L, Marelli C, Bilezikian JP. Gosmanova EO, et al. Among authors: bilezikian jp. Rev Endocr Metab Disord. 2021 Jun;22(2):297-316. doi: 10.1007/s11154-020-09613-1. Epub 2021 Feb 18. Rev Endocr Metab Disord. 2021. PMID: 33599907 Free PMC article. Review.
Data for renal disease that encompassed a range of renal insufficiency to chronic kidney disease were reported in 10 articles; the reported rates ranged from 2.5% to 41%. In patients who receive long-term treatment with oral calcium and active vitamin D, chronic hypoparath …
Data for renal disease that encompassed a range of renal insufficiency to chronic kidney disease were reported in 10 articles; the reported …
50 results